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Abstract: Antibiotic resistance is a major challenge in management of 
infectious diseases globally, and particularly in developing countries. There 
are few studies that have analysed the impact of such abuse on the 
development of bacterial resistance in Nigeria and sub Saharan Africa. To 
this end, we retrospectively analysed ciprofloxacin susceptibility patterns in 
a secondary healthcare facility in Northwest Nigeria over a four year period. 
Three hundred and thirty six pathogens isolated from 370 patients were 
analysed in this study. The common pathogens isolated from wound 
infections were Staphylococcus aureus (29, 7.84%), Pseudomonas spp (10, 
2.7%) and Proteus spp (7, 1.89%). In stool samples, Proteus (11, 2.97%), 
Escherichia coli (8, 2.2%) and Salmonella (6, 1.62%) were the most 
commonly isolated organisms respectively. While for urine samples, 
isolates were S. aureus (105, 28.37%) followed by E. coli from urine 
samples (62, 16.76%). During the study period, we observed there was a 
high degree of resistance to ciprofloxacin among Proteus spp (50%), E. coli 
(41.3%), S. aureus (20.6%), Klebsiella (20%) and Pseudomonas (20%). 
Government and stakeholders need to urgently develop antimicrobial 
stewardship programmes that will address the issue of antibiotic resistance 
in the country. 
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Introduction 
The use of antibiotics in clinical 
practice represents one of the 
tremendous achievements in the 
control of infectious diseases. 
However, the effectiveness of 
antibiotics has been reduced by an 
increasing threat of 
bacterial resistance. Antibiotic 
resistance (ABR) is the ability of 
bacteria to survive 
in antibiotic concentrations that would 
normally inhibit or kill the bacteria[1]. 
ABR has emerged as one of the 
greatest challenges for clinical 
microbiologists and healthcare 
practitioners worldwide 
today[2].Globally, deaths from 
antibiotic resistant bacteria are 
estimated to be around 700,000 
annually, and projected to rise to 10 
million deaths by 2050[3]. 
Fluoroquinolones are among the most 
frequently prescribed antimicrobial 
agents worldwide, since the expiry of 
the patent on this class of drugs. The 
European Antimicrobial Resistance 
Surveillance Network (EARS-Net 
report, indicates a significant increase 
in fluoroquinolone resistance across 
Europe since 2001, with levels ranging 
from 7% to 53% in 2007[4]. 
Fluoroquinolones, derivatives of 
quinolones are stable, orally 
administrable, broad spectrum agents 
used to treat a range of bacterial 
infections. A commonly prescribed 
fluoroquinolone in developing 
countries is ciprofloxacin which has 
broad spectrum activity in treatment of 
complicated and uncomplicated 
bacterial infectionsin several 
anatomical sites, such as respiratory 
tract infections, otitis media, sinusitis, 
eye infections, UTI and sepsis [5]. For 
close to two decades, fluoroquinolones 
were antibiotics of choice for acute 
respiratory, enteric and urinary tract 
infections as well as serious systemic 
infections such as bacteremia[6]. The 
frequent prescription of these drugs by 
healthcare providers, indiscriminate 
antibiotic use and substandard drugs in 
developing countries including Nigeria 
has contributed to the continued spread 
of ABR to fluoroquinolones[7]. 
 
Quinolone resistance in enterobacteria
ceae is well documented, and is 
usually the result of chromosomal 
mutations leading to alterations in 
target enzymes or drug 
accumulation[8]. Single nucleotide 
polymorphisms in the quinolone 
resistance determining regions 
(QRDR) of gyrA and parC, two of the 
genes that encode DNA gyrase and 
topoisomerase IV respectively, can 
lead to conformational changes in 
these enzymes that prevents 
quinolones from binding but still 
preserve their enzymatic 
function[9,10]. Mutations in the 
QRDRs of gyrA and parC are the most 
commonly documented quinolone 
resistance mechanisms, but resistance 
is also known to be conferred by 
mutations in the second topoisomerase 
gene, pare [11]. Quinolone resistance 
can also be acquired horizontally 
through transferable aac(6')-Ib or 
quinolone resistance (qnr) DNA. 
AAC(6')-Ib encodes a ciprofloxacin 
acetylating enzyme, while the product 
of qnr inhibits quinolones binding to 
target proteins [12]. More recently, 
however, plasmid-mediated 
quinolone resistance has been reported 
in K. pneumoniae and E. coli, 
associated with acquisition of the qnr 
gene[8,10,13]. Other ABR 
mechanisms in bacteria include 
alteration of cell permeability, site of 
action of the antibiotic or the release of 
degrading enzymes[14,15] 
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In resource poor settings, poor 
infrastructure, lack of trained 
laboratory personnel and weak 
surveillance for ABR contributes to 
the spread of ABR bacteria. In Nigeria, 
as with most of SSA there are very few 
published reports on ABR to 
fluoroquinolones [6,16], with no 
published report from Northwest 
Nigeria. To this end, this study aimed 
to retrospectively 
analyseciprofloxacinsusceptibility 
patterns of commonly isolated bacteria 
in a secondary health care facility in 
Kebbi state, Northwest Nigeria. 
 
Materials and Methods 
Ethical approval: This study did not 
carry out any invasive procedures and 
patients’ clinical information was not 
revealed to the researchers. Ethical 
approval for use of data was granted 
by the management of Aisha 
Muhammadu Buhari General Hospital, 
Jega, Kebbi State Nigeria. 
 
Setting: Jega local government area 
(LGA) is one of the twenty-one LGAs 
in Kebbi state belonging to the 
Gwandu emirate. Jega LGA has a 
projected population based on 2006 
census of 270,517, comprising mostly 
muslims, farmers and other low 
income earners. Jega has only one 
General hospital (AMBGH) and two 
private hospitals that provide basic 
health care services. 
 
Aisha Muhammadu Buhari General 
Hospital (AMBGH): AMBGHhas an 
80 bed capacity and serves a rural 
population from villages and 
settlements within Jega LGA. The 
hospital provides services in diagnosis, 
curative, promotive and rehabilitative 
services in medical treatment and an 
outpatient clinic. AMBGH is staffed 
by one physician supported by fifteen 
nurses and midwives, and a 
microbiology laboratory led by a 
qualified laboratory scientist. The 
facility has minimal laboratory 
facilitiesand can only carry out urine, 
stool, sputum culture, microscopy, 
biochemical, immunological tests, 
HIV screening and tuberculosis 
testing.  
 
Sample collection: This was a 
retrospective study of the data on 
fluoroquinolone resistance patterns 
carried out in Jega local government 
area (LGA), Kebbi state, Northwest 
Nigeria, at the department of 
microbiology of (AMBGH), Jega, 
Kebbi State Nigeria. All microbiology 
reports for urine, stool, vaginal swabs 
and wound samples between June 
2014 and September 2017 were 
included for analysis. For this study, 
we excluded data with incomplete 
sensitivity results, and all samples for 
microbiological analysis were referred 
to the laboratory by the physician. 
 
Microbiological analyses: Patients 
referred to the microbiology laboratory 
by the physician were provided with 
labelled specimen bottles and trained 
on how and when to provide samples 
for laboratory diagnosis. All samples 
brought to the laboratory were 
immediately processed following 
standard bacteria culture procedures. 
Biochemical characterization of 
isolates was carried out under the strict 
supervision of a medical laboratory 
scientist licensed by the Medical and 
Laboratory Science Council of Nigeria 
(MLSCN). Antibiotic susceptibility 
testing was carried out following the 
Clinical Laboratory Standards Institute 
(CLSI) guidelines [27]. In this study, 
we report the rates of susceptibility 
and resistant isolates. AMBGH 
microbiology laboratory is regularly 
subjected to external audits by the 
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MLSCN to assess the state of the 
facility for providing routine 
diagnostic services.   
 
Statistics: Data were accumulated and 
analysed with Microsoft excel and 
Stata version 12 software (College 
Station, Texas, USA) to generate 
differential descriptive statistics 
including frequency tables thatshowed 
the frequency and percentage 
distribution of isolates. 
 
 
Results 
Demographics 
In total three hundred and seventy 
patients were sampled at the 
microbiology laboratory of AMBGH 
between June 2014 and September 
2017. For the study period reviewed, 
the ratio of male to female sampled 
was 0.47:1.0, and the median age of 
the children was 10 yrs (IQR, 15 yrs) 
and that of adults was 35 yrs (IQR, 21 
yrs) respectively (Table 1).  
 
Bacteria spectrum 
In total 336 isolates were included 
within the study period reviewed. 
There were no significant differences 
(P=0.09) in the isolates collected 
among children or adults (Table 2). 
The most frequent isolate was 
Staphylococcus aureus from urine 
samples (105, 28.37%) followed by 
Escherichia coli from urine samples 
(62, 16.76%). From wound infections 
the most frequent isolate was S. aureus 
(29, 7.84%), followed by 
Pseudomonas spp (10, 2.7%) and 
Proteus spp (7, 1.89%). In stool 
samples, Proteus (11, 2.97%), E. coli 
(8, 2.2%) and Salmonella (6, 1.62%) 
were the most commonly isolated 
organisms respectively (Table 3). 
Other samples such as sputum and 
high vaginal swabs revealed S. aureus 
to be the main pathogenic organism 
isolated in culture. 
 
Antibiotic susceptibility 
Next we assessed the proportion of 
isolates that were not susceptible to 
ciprofloxacin from antibiotic 
sensitivity tests carried out using the 
disk diffusion method. During the 
study period, we observed there was a 
high degree of resistance to 
ciprofloxacin among Proteusspp 
(50%), E. coli (41.3%), S. aureus 
(20.6%), Klebsiella (20%) and 
Pseudomonas (20%) respectively. 
Susceptibility to ciprofloxacin by the 
isolates was highest in Salmonella 
(71.4%), S. aureus (65.2%), Klebsiella 
(60%), Pseudomonas (60%), E. coli 
(41.3%), and Proteus (40%) 
respectively. Other isolates within the 
study period reviewed demonstrated 
intermediate level susceptibility (Table 
4). 
 
Discussion 
In developing countries, antibiotics use 
without prescription due to their 
availability over the counter appears to 
be the norm, in addition to sub-optimal 
health care systems that lack the 
capacity to provide timely laboratory 
results for clinicians to make decisions 
with. These issues and others promote 
the rapid increase in the spread of 
antibiotics resistant bacteria in 
resource poor settings. Here we review 
four year microbiological data from a 
secondary health care facility in a rural 
area in Northwest Nigeria. This was 
carried out in order to provide valuable 
laboratory information for clinicians 
and health care practitioners on the 
pattern of ciprofloxacin susceptibility, 
in the absence of routine antibiotic 
resistance surveillance activities. Our 
data suggests that the most commonly 
isolated pathogen from samples and 
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swabs analysed was S. aureus, 
followed by E. coli. Our findings also 
revealed a high degree of ciprofloxacin 
resistance in the isolates, with Proteus 
spp demonstrating most resistance 
(50%), followed by E. coli(41.3%). In 
a five year retrospective study carried 
out in Bahia, Brazil a high degree of 
ciprofloxacin resistance was observed 
in community acquired urinary tract 
infection isolates from the participants. 
Ciprofloxacin resistance was highest in 
E. coli isolates, with up to 36% of the 
isolates in a particular year being 
resistant[17]. In a retrospective study 
in Gabon, ciprofloxacin resistance of 
24.1% was also reported in E. coli[18]. 
Quinolone resistance has also been 
reported in Cameroon from S. Typhi 
and Ghana inVibrio cholerae 
respectively [19,20]. Studies on 
fluoroquinolones resistance in Africa, 
including Nigeria are very scarce. The 
few published papers on 
fluoroquinolones resistance in Nigeria 
clearly suggest the circulation of 
ciprofloxacin resistant bacteria in the 
country[16,21–25]. In a study carried 
out in Minna, north central Nigeria, the 
authors found that Salmonella enterica 
serovar Typhi were resistant to 
commonly prescribed antibiotics 
ceftriaxone, cefuroxime, amoxicillin, 
ampicillin, ciprofloxacin, and 
augmentin[26]. The increase in 
treatment failures to β-lactams and 
sulfamethoxazole+trimethoprim over 
the past years led to the use of 
fluoroquinolones as the first choice, 
hence putting pressure on the use of 
this drug as first line therapy for most 
bacterial infections. 
 
The review of microbiological data 
from the secondary health care facility 
in this study reveals an alarming trend 
of ciprofloxacin resistance in the 
population. Our study also provides 
local ABR data which could be used 
by clinicians in the region to guide 
clinical decisions. Ciprofloxacin, a 
broad spectrum antibiotic is widely 
used in management of infections in 
developing countries. Our study 
suggests the need to establish 
surveillance for ABR in Nigeria and 
Africa in general, replicating the 
approach of the European 
Antimicrobial Resistance Surveillance 
Network 
(http://ecdc.europa.eu/en/activities/sur
veillance/ EARS-
Net/Pages/index.aspx), which monitors 
antibiotic consumption in comparison 
to spread of resistance. In developing 
countries, the challenge of managing 
the spread of ABR is enormous, owing 
to lack of good sanitation practices, 
lack of potable water, poor hygiene, 
high poverty levels, illiteracy and sub-
optimal healthcare systems. Hence, 
there is a need for African 
governments to have short term goals 
that will produce significant results in 
dealing with the menace of ABR. 
 
This study has some limitations, first is 
the inability of the health facility 
considered in this study to carry out 
blood culture to isolate pathogens in 
the blood of patients. Lack of blood 
culture facility is one of the major 
challenges facing diagnostic 
laboratories in Africa, and even when 
present, the approach used might be 
sub-optimal or lack the required 
sensitivity. Inability to carry out blood 
culture in this facility has potentially 
excluded bacteria that might be 
important in our understanding of the 
ciprofloxacin resistant bacteria 
circulating in the population. Second, 
incessant power cut offs also made it 
impossible for the facility to preserve 
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multidrug resistant isolates for 
molecular studies. Hence the 
underlying molecular mechanisms of 
resistance in the isolates are unclear. 
Third, the isolates described here do 
not distinguish between community or 
hospital acquired infections based on 
the records made available by the 
health facility. Lastly, it is possible 
that the number of isolates reported in 
this study might be below the true 
number of isolates actually reported 
due to poor record keeping which is 
common to most African hospitals, but 
that might not be the case in our study. 
 
To conclude, it is very likely that 
fluoroquinolones resistance emerged 
with increase in their indiscriminate 
use [6], hence there is an urgent need 
for establishing an antimicrobial 
stewardship programme that will 
address antibiotic use in humans and 
animals. This programme should be 
designed to complement improving the 
quality of laboratories, and 
establishing a national surveillance 
programme to detect, report and 
monitor multidrug resistant bacteria 
strains. 
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Table 1. Demographics of patients 
 Children (≤ 18 yrs) Adult (> 18 yrs) 
 54 316 
Median age ( IQR) 10 35 
 Male Female 
Sex, n (%) 119 (32.2%) 251 (67.8%) 
 
 
Table 2. Distribution of isolates from children and adults 
Isolates Proteu
s spp 
Klebsiell
a 
Pseudomona
s 
Staphylococcu
s 
aureus 
Escherichi
a coli 
Salmonell
a 
Childre
n (≤18 
yrs) 
7 - 3 28 14 2 
Adults 
(>18 
yrs) 
23 10 7 176 61 5 
Total 30 10 10 204 75 7 
 
 
Table 3. Source of isolates from patients’ samples 
Samples Proteu
s spp 
Klebsiell
a 
Pseudomona
s 
Staphylococcu
s 
Escherichi
a coli 
Salmonell
a 
Wound 
infection
s 
7 3 10 29 - - 
Urine 
infection
s 
21 7 - 105 62 1 
High 
vaginal 
swab 
- - - 20 4 - 
Sputum  - - - 50 1 - 
Stool 11 - - - 8 6 
Total 30 10 10 204 75 7 
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Table 4. Susceptibility pattern of bacterial isolates to ciprofloxacin 
Samples Proteu
s spp 
Klebsiell
a 
Pseudomon
as 
Staphylococc
us 
Escherichi
a coli 
Salmonell
a 
Susceptible 12 
(40%) 
6 (60%) 6 (60%) 133 (65.2) 31 
(41.3%) 
5 (71.4%) 
Intermediat
e 
3 
(10%) 
2 (20%) 2 (20%) 29 (14.2%) 13 
(17.4%) 
1 (14.3%) 
Resistant 15 
(50%) 
2 (20%) 2 (20%) 42 (20.6%) 31 
(41.3%) 
1 (14.3%) 
Total 30 
(100%
) 
10 
(100%) 
10 (100%) 204 (100%) 75 (100%) 7 (100%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 45 
